Four hundred eighteen previously untreated MM patients without BRAF mutation were randomly assigned to nivolumab (at a dose of 3 mg/kg Q2W and dacarbazine-matched placebo Q3W) or dacarbazine (at a dose of 1000 mg/m2 of body-surface area Q3W and nivolumab-matched placebo Q2W). The gene discussed is BRAF; the disease is Miyoshi myopathy.